combination chemotherapy followed by radiation therapy in treating patients with medulloblastoma, supratentorial primitive neuroectodermal tumor, or ependymoma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating patients who have surgically resected, newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely resected ependymoma.

objectives: * determine the toxicity of adjuvant dose-intensive induction chemotherapy with cisplatin, vincristine, cyclophosphamide, and etoposide with or without methotrexate followed by standard radiotherapy in patients with surgically resected, newly diagnosed high stage medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely resected ependymoma. * determine the response rate, time to progression, overall survival, and pattern of failure in these patients treated with this regimen. outline: patients receive dose-intensive induction chemotherapy consisting of cisplatin iv over 6 hours on day 0; vincristine iv on days 0, 7, and 14; and etoposide and cyclophosphamide iv over 1 hour on days 1 and 2. patients with m1+ disease (i.e., evidence of dissemination beyond primary tumor site) also receive methotrexate iv over 4 hours on day 3. patients receive filgrastim (g-csf) subcutaneously daily beginning on day 7 and continuing until blood counts recover. chemotherapy continues every 21-28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity. patients then undergo radiotherapy 5 days a week for 6.5 weeks beginning 3-6 weeks after completion of chemotherapy. patients are followed at 6 weeks, then every 3 months for 2 years, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter. projected accrual: a total of 6-20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histological confirmation of one of the following: * high stage medulloblastoma with neuraxis dissemination (chang stage m1 or greater) * primitive neuroectodermal tumor * ependymoma * incompletely resected on postoperative mri or neurosurgical report * definitive prior surgery within 42 days of study patient characteristics: age: * 10 to 65 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * bilirubin less than 1.5 mg/dl * sgpt less than 2.5 times upper limit of normal renal: * creatinine clearance greater than 60 ml/min prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy endocrine therapy: * prior corticosteroids allowed * no concurrent corticosteroids as antiemetics radiotherapy: * no prior radiotherapy surgery: * see disease characteristics

Keywords: childhood infratentorial ependymoma childhood supratentorial ependymoma adult medulloblastoma adult myxopapillary ependymoma adult anaplastic ependymoma adult ependymoblastoma untreated childhood supratentorial primitive neuroectodermal tumor untreated childhood medulloblastoma newly diagnosed childhood ependymoma adult supratentorial primitive neuroectodermal tumor (pnet)